Duquesne Family Office, founded by Stanley Druckenmiller, is a single-family office that employs a flexible investment strategy across global markets, focusing on wealth preservation and growth through macroeconomic and bottom-up approaches. The firm pursues concentrated, research-driven positions in global public equities, venture investments, and credit opportunities, with a notable emphasis on cutting losses quickly and amplifying strong positions.
40% of their portfolio is in Healthcare. Deal activity decreased year-over-year (1 deals in the last 12 months vs 2 prior). Their most common stage is series-b (40% of deals). Average disclosed round size is $71.1M (across 4 rounds with reported amounts).
Portfolio
5
Fund Size
$4.5B
Top Stage
Series B
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 MyOme | Unknown | — | Dec 2025 |
 Precision Neuroscience Corporation | Series C | $102M | Dec 2024 |
 MetOx International, Inc. | Series B | $15M | Nov 2024 |
| CC2i Genomics | Series C | $100M | Apr 2021 |
 Lean Technologies | Series B | $67.5M | — |
Top Co-Investors
Last updated: 16 April 2026